Cure My Disease

Don't miss your cure!

 Log in / Sign up

Folate-Targeted PET tracer aims to light up hidden artery inflammation

NCT ID NCT07877324

Diagnosis Sponsor: Turku University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 16, 2026 · Last updated Oct 16, 2026

Summary

Researchers are testing a new PET imaging tracer called 18F-AlF-NOTA-Folate to see whether it can detect inflammation inside atherosclerotic plaques throughout the body. The tracer binds to folate receptor beta, a marker on activated immune cells called macrophages that drive vascular inflammation. About 90 people with suspected or stable coronary artery disease, or a recent heart attack, will receive the tracer and undergo PET and CT scans of the heart and major arteries. The study also tracks participants for up to five years to see whether imaging findings relate to later cardiovascular events.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-AlF-NOTA-Folate, an experimental PET imaging tracer that binds to folate receptor beta on activated immune cells
What this could lead to
If it works, this tracer could give doctors a non-invasive way to see inflammation throughout the arteries, which may help identify plaques that are more likely to cause future heart problems.
What could go wrong
This is an early imaging study with 90 participants, so it may not show that tracer uptake reliably tracks inflammation or predicts heart events. The tracer is experimental and not yet approved for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2026

Expected to finish

Dec 2032

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Group A: \- Patients aged 50-80 years with suspected coronary artery disease who have undergone coronary CT angiography and are referred for cardiac 15O-water PET perfusion imaging based on suspected obstructive coronary artery disease. Group B: \- Patients aged 50-80 years with a recent myocardial infarction. For both group A and B: \- Written informed consent. Exclusion Criteria: * unstable angina symptoms * previous myocardial infarction (Group A) * previous coronary artery bypass grafting or previous percutaneous coronary intervention * severe pulmonary disease * severe symptomatic asthma * severe valvular disease * uncontrolled hypertension (\>180/110 mmHg) * severe hypotension (systolic blood pressure \<100 mmHg) * severe renal failure * pregnancy * age \<50 or \>80 years * second- or third-degree atrioventricular block or sick sinus syndrome without a pacemaker * allergy to X-ray contrast agents * known inflammatory disease, including rheumatic or autoimmune disease, sarcoidosis, or myocarditis * known infection * use of anti-inflammatory medication or folate antagonists such as corticosteroids or methotrexate; known cancer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atheroscleroses are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis coronary artery disorder Inflammation inflammatory disease myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atheroscleroses Inflammation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Turku PET Centre

    RECRUITING

    Turku, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.